You are viewing: North America Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The North America Nuclear Medicine Market was valued at $3069.2 Million in 2025 and projected to reach to $5801.6 Million by 2030, representing a compound annual growth rate of 13.6%. North America's nuclear medicine market is poised for sustained expansion through 2030, driven by increasing prevalence of chronic diseases, aging demographics, and growing demand for precise diagnostic imaging.

North America Nuclear Medicine Market Trends and Insights

  • North America's advanced healthcare infrastructure, high adoption of diagnostic imaging technologies, and strong reimbursement frameworks are driving market expansion.
  • The region benefits from significant investments in medical research and development, coupled with an aging population requiring advanced diagnostic and therapeutic nuclear medicine procedures. North America's 13.6% compound annual growth rate reflects increasing demand for PET/CT imaging, SPECT applications, and targeted radionuclide therapies.
  • North America's regulatory environment, led by the FDA, supports innovation in radiopharmaceuticals and imaging equipment.
  • Healthcare providers across North America are integrating nuclear medicine into comprehensive cancer care, cardiology, and neurology programs, positioning the region as a leader in clinical adoption and technological advancement through 2030..

Key Market Statistics

  • CAGR (2025-2030) 13.6% CAGR
  • Market Size, 2025 ~USD 3069.2 Million
  • Forecast, 2030 ~USD 5801.6 Million
  • Geography North America

North America Nuclear Medicine Market Overview

Market Valuation & Growth :

North America's nuclear medicine market is valued at $3,069.2 million in 2025, with a robust CAGR of 13.6%, projected to reach $5,801.6 million by 2030, demonstrating strong regional demand for advanced diagnostic imaging.

Advanced Healthcare Infrastructure :

The region benefits from state-of-the-art medical facilities, cutting-edge diagnostic imaging technology adoption, and well-established clinical protocols that support widespread nuclear medicine utilization across hospitals and imaging centers.

Strong Reimbursement Framework :

Favorable reimbursement policies from Medicare, Medicaid, and private insurers in the US and Canada create a supportive environment for nuclear medicine procedures, driving accessibility and market expansion.

Research & Development Investment :

Significant investments in medical research and development across North America fuel innovation in radiopharmaceuticals, imaging equipment, and diagnostic protocols, positioning the region as a leader in nuclear medicine advancement.

North America Nuclear Medicine Market Dynamics

  • The region's mature healthcare system and robust reimbursement infrastructure create favorable conditions for market penetration and technology adoption.
  • Healthcare providers are increasingly integrating nuclear medicine into comprehensive diagnostic protocols, particularly for oncology, cardiology, and neurology applications.
  • Continued investment in radiopharmaceutical development and hybrid imaging technologies will further accelerate market growth.
  • The competitive landscape remains dynamic, with major medical device manufacturers and pharmaceutical companies expanding their North American presence to capitalize on this lucrative market opportunity..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • North America's nuclear medicine market will nearly double from $3,069.2M (2025) to $5,801.6M (2030), driven by 13.6% CAGR.
    • North America leads in PET/CT and SPECT adoption, supported by advanced healthcare infrastructure and strong reimbursement policies.
    • North America's aging demographic and rising cancer prevalence are key growth catalysts for diagnostic and therapeutic nuclear medicine procedures.
    • North America's FDA-regulated innovation ecosystem accelerates radiopharmaceutical development and imaging technology advancement.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2039
    Growth Rate CAGR of 15.1% from 2025 to 2039
    Largest Segment DIAGNOSTIC PROCEDURES (Procedure)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2039)
    Segments Covered Type, Application, Procedure, End User

    North America Nuclear Medicine Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Bone Metastasis
    • Bone Scans
    • Brachytherapy Isotopes
    • Cardiology
    • Cs-131
    • Diagnostic Nuclear Medicine
    • Endocrine Tumors
    • F-18
    • Ga-67
    • I-123
    • I-125
    • I-131
    • Ir-192
    • Lu-177
    • Lymphoma
    • Neurology
    • Oncology
    • Other Beta Emitters
    • Other Brachytherapy Isotopes
    • Other Pet Applications
    • Other Pet Radiopharmaceuticals
    • Other Spect Applications
    • Other Spect Radiopharmaceuticals
    • Other Therapeutic Applications
    • Pd-103
    • Pet Applications
    • Pet Procedures
    • Pet Radiopharmaceuticals
    • Pulmonary Scans
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Applications
    • Spect Procedures
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Thyroid
    • Tl-201
    • Y-90

    By Application

    • Diagnostic Applications
    • Therapeutic Applications

    By Procedure

    • Diagnostic Procedures
    • Therapeutic Procedures

    By End User

    • Academic & Research Institutes
    • Diagnostic & Imaging Centers
    • Hospitals
    • Other End Users

    Target Audience

    • Medical Device Manufacturers : Require detailed North American market insights to develop region-specific product strategies, optimize distribution networks, and identify growth opportunities in diagnostic imaging equipment.
    • Pharmaceutical & Radiopharmaceutical Companies : Need market intelligence on nuclear medicine adoption rates, reimbursement policies, and clinical demand patterns to guide R&D investments and commercialization strategies in North America.
    • Healthcare Facility Operators : Seek market data to justify capital investments in nuclear medicine departments, assess competitive positioning, and plan service expansion based on regional demand forecasts.
    • Investment & Private Equity Firms : Require comprehensive market analysis to evaluate investment opportunities in nuclear medicine companies, assess growth potential, and identify acquisition targets within North America.
    • Healthcare Consultants & Analysts : Need authoritative market data and regional insights to support client advisory services, competitive benchmarking, and strategic planning recommendations for North American healthcare organizations.

    Key Companies in the North America Nuclear Medicine Market

    CompanyHQOwnershipStrongest segments
    BIOMERIEUX S.A.FrancePublic CompanySPECT,PET,Beta Emitters,
    CARL ZEISS AGGermanyPublic CompanyPET (F-18),SPECT (Tc-99m),
    ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanySPECT,PET,Brachytherapy,
    BRUKER CORPORATIONUnited StatesPublic CompanyPET,SPECT,Beta Emitters,
    SHIMADZU CORPORATIONJapanPublic CompanyPET (F-18),SPECT (Tc-99m),Alpha Emitters,
    VARIAN MEDICAL SYSTEMS, INCUnited StatesPrivate CompanyBrachytherapy,Linear Accelerators,Software Solutions,
    LEONI AGGermanyPrivate CompanyPET Systems,SPECT Systems,Beta Emitters,
    PFIZERUnited StatesPublic CompanyPET (F-18),Beta Emitters (Y-90, Lu-177),SPECT (Tc-99m),
    ELEKTA ABSwedenPublic CompanyBrachytherapy,Linear Accelerators,Stereotactic Radiosurgery,
    NOVARTIS AGSwitzerlandPublic CompanyBeta Emitters,SPECT,Alpha Emitters,
    LANTHEUS HOLDINGS, INC.United StatesPublic CompanyPET,SPECT,Beta Emitters,
    GE HEALTHCAREUnited StatesPublic CompanySPECT,PET,Brachytherapy,
    TELIX PHARMACEUTICALS LIMITEDAustraliaPublic CompanyPET Imaging,Therapeutics,Manufacturing Solutions,
    SIEMENS HEALTHINEERSGermanyPublic CompanyPET,SPECT,Beta Emitters,
    CHINA ISOTOPE & RADIATION CORPORATIONChinaPublic CompanySPECT,PET,Beta Emitters,
    BAYER AGGermanyPublic CompanySPECT,PET,Alpha Emitters,
    CARDINAL HEALTHUnited StatesPublic CompanySPECT,PET,Beta Emitters,

    BIOMERIEUX S.A.

    bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

    CARL ZEISS AG

    Carl Zeiss AG is a German public company founded in 1846 with 5,798 employees. The company specializes in optical systems and precision instruments.

    ATS AUTOMATION TOOLING SYSTEMS INC

    ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company provides automation and tooling solutions.

    BRUKER CORPORATION

    Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical solutions.

    SHIMADZU CORPORATION

    Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees. The company manufactures analytical and scientific instruments.

    VARIAN MEDICAL SYSTEMS, INC

    Varian Medical Systems, Inc. is a United States private company founded in 1948 with 10,000 employees. The company specializes in medical devices and radiation oncology solutions.

    LEONI AG

    Leoni AG is a German private company founded in 1569 with 95,090 employees. The company manufactures cables, wiring systems, and related products.

    PFIZER

    Pfizer is a United States public company founded in 1849 with 75,000 employees. The company is a major pharmaceutical manufacturer and developer.

    ELEKTA AB

    Elekta AB is a Swedish public company founded in 1972 with 4,353 employees. The company specializes in radiation therapy and radiosurgery solutions.

    NOVARTIS AG

    Novartis AG is a Swiss public company founded in 1996 with 75,267 employees. The company is a leading pharmaceutical and healthcare company.

    LANTHEUS HOLDINGS, INC.

    Lantheus Holdings, Inc. is a United States public company founded in 1956 with 1,193 employees. The company develops diagnostic imaging agents and radiopharmaceuticals.

    GE HEALTHCARE

    GE Healthcare is a United States public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

    TELIX PHARMACEUTICALS LIMITED

    Telix Pharmaceuticals Limited is an Australian public company founded in 2015 with 1,152 employees. The company develops diagnostic and therapeutic radiopharmaceuticals.

    SIEMENS HEALTHINEERS

    Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company provides medical imaging, diagnostics, and healthcare solutions.

    CHINA ISOTOPE & RADIATION CORPORATION

    China Isotope & Radiation Corporation is a Chinese public company founded in 1983 with 3,578 employees. The company operates in the isotope and radiation sector.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees. The company operates in pharmaceuticals, crop science, and consumer health.

    CARDINAL HEALTH

    Cardinal Health is a United States public company founded in 1979 with 55,392 employees. The company is a healthcare services and products distributor.

    North America vs. other regions

    HowNorth America compares to the other 3 regional blocs covered in this market.

    Global
    ~USD 21.01 Million · 15.1% wtd CAGR ·
    Europe
    ~USD 3132.3 Million · 14.6% wtd CAGR ·
    Asia Pacific
    ~USD 2850 Million · 15.9% wtd CAGR ·
    Latin America
    ~USD 513.9 Million · 7.5% wtd CAGR ·
    Middle East & Africa
    ~USD 474.4 Million · 11% wtd CAGR ·

    Countries within North America - compare and drill down

    Country2025 size (native)
    USUSD 9155.5 Million
    CanadaUSD 402.7 Million

    Country market size visualization

    US
    USD 9155.5 Million
    Canada
    USD 402.7 Million

    Reasons to Buy this Report

    • Country-Level Market Breakdown : Access detailed market sizing for US and Canada, enabling precise market entry strategies and competitive positioning within North America's largest nuclear medicine markets.
    • Growth Trajectory Analysis : Understand the 13.6% CAGR drivers specific to North America, including demographic trends, technology adoption rates, and reimbursement dynamics that differ from global markets.
    • Reimbursement & Regulatory Insights : Gain intelligence on North American reimbursement frameworks, FDA approval pathways, and healthcare policy impacts that directly influence market opportunities and investment decisions.
    • Competitive Landscape Intelligence : Identify key market players, their regional strategies, and competitive positioning within North America's advanced healthcare ecosystem to inform business development initiatives.
    • Investment & Expansion Planning : Leverage comprehensive market data to support capital allocation decisions, facility expansion plans, and partnership strategies tailored to North America's high-growth nuclear medicine sector.

    Frequently asked questions

    What is the projected market size for nuclear medicine in North America by 2030?

    North America's nuclear medicine market is projected to reach $5,801.6 million by 2030, up from $3,069.2 million in 2025.

    What is the CAGR for North America's nuclear medicine market?

    North America's nuclear medicine market is expected to grow at a compound annual growth rate of 13.6% between 2025 and 2030.

    What factors are driving growth in North America's nuclear medicine market?

    North America's growth is driven by advanced healthcare infrastructure, aging population demographics, rising cancer incidence, strong reimbursement frameworks, and FDA-supported innovation in radiopharmaceuticals.

    Which imaging modalities are most prevalent in North America's nuclear medicine market?

    PET/CT and SPECT imaging are the dominant modalities in North America, supported by widespread clinical adoption and strong healthcare provider investment.

    How does North America's regulatory environment impact the nuclear medicine market?

    North America's FDA regulatory framework promotes innovation in radiopharmaceuticals and imaging equipment, accelerating market growth and clinical adoption of advanced nuclear medicine technologies.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status